William T. Lowther, Ph.D., Associate Professor Biochemistry

William T. Lowther, Ph.D.

Associate Professor, Biochemistry
Comprehensive Cancer Center

Contact Information

Academic: 336-716-7230 | Department: 336-716-7230

Email: tlowther@wakehealth.edu

Education & Training

Ph.D., University of Florida , 1994
B.S., Stetson University , 1989
Fellowship, Molecular Biology, University of Florida College of Medicine, 2002

Memberships

Am Chemical Society
American Crystallographic Asso
Am Soc Of Biochem & Mol Biolog

William T. Lowther, Ph.D.

Associate Professor, Biochemistry Comprehensive Cancer Center

Research Interests

cancer/oncogenesis, drugs/therapeutic agents pharm, metabolism, rare diseases, structural biology

Contact Information

Academic: 336-716-7230 | Department: 336-716-7230

Email: tlowther@wakehealth.edu

Recent Publications

Chen H, Gu Z, Zhang H, Wang M, Chen W, Lowther WT, Chen YQ. Expression and purification of integral membrane fatty acid desaturases. PLoS One. 2013;8(3):e58139.

Jiang J, Johnson LC, Knight J, Callahan MF, Riedel TJ, Holmes RP, Lowther WT. Metabolism of [13C5]hydroxyproline in vitro and in vivo: implications for primary hyperoxaluria. Am J Physiol Gastrointest Liver Physiol. 2012;302(6):G637-G643.

Lema Tome CM, Palma E, Ferlaga S, Lowther WT, Hantgan R, Wykosky J, Debinski W. Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. J Biol Chem. 2012;287(17):14012-22.

Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta. 2012;1822(10):1544-1552.

Lowther WT, Haynes AC. Reduction of cysteine sulfinic acid in eukaryotic, typical 2-Cys peroxiredoxins by sulfiredoxin. Antioxid Redox Signal. 2011;15(1):99-109.

Riedel TJ, Johnson LC, Knight J, Hantgan RR, Holmes RP, Lowther WT. Structural and biochemical studies of human 4-hydroxy-2-oxoglutarate aldolase: implications for hydroxyproline metabolism in primary hyperoxaluria. PLoS ONE. 2011;6(10):e26021.

Klomsiri C, Nelson KJ, Bechtold E, Soito L, Johnson LC, Lowther WT, Ryu S-E, King SB, Furdui CM, Poole LB. Use of dimedone-based chemical probes for sulfenic acid detection evaluation of conditions affecting probe incorporation into redox-sensitive proteins. Methods Enzymol. 2010;473():77-94.

Cox AG, Pearson AG, Pullar JM, Jonsson TJ, Lowther WT, Winterbourn CC, Hampton MB. Mitochondrial peroxiredoxin 3 is more resilient to hyperoxidation than cytoplasmic peroxiredoxins. Biochem J. 2009;421(1):51-58.

Jonsson TJ, Johnson LC, Lowther WT. Protein engineering of the quaternary sulfiredoxin.peroxiredoxin enzyme.substrate complex reveals the molecular basis for cysteine sulfinic acid phosphorylation. J Biol Chem. 2009;284(48):33305-10.

Jonsson TJ, Johnson LC, Lowther WT. Structure of the sulphiredoxin-peroxiredoxin complex reveals an essential repair embrace. Nature. 2008;451(7174):98-101.

Murray MS, Holmes RP, Lowther WT. Active site and loop 4 movements within human glycolate oxidase: implications for substrate specificity and drug design. Biochemistry. 2008;47(8):2439-2449.

Jonsson TJ, Tsang AW, Lowther WT, Furdui CM. Identification of intact protein thiosulfinate intermediate in the reduction of cysteine sulfinic acid in peroxiredoxin by human sulfiredoxin. J Biol Chem. 2008;283(34):22890-94.

Jonsson TJ, Murray MS, Johnson LC, Lowther WT. Reduction of cysteine sulfinic acid in peroxiredoxin by sulfiredoxin proceeds directly through a sulfinic phosphoryl ester intermediate. J Biol Chem. 2008;283(35):23846-51.

Brunell DJ, Lowther T, Sagher D, Brot N, Weissbach H. A disulfide intermediate is required for the reduction of methionine sulfoxide reductase by thioredoxin [abstract]. FASEB J. 2007;21(5):A275.

Lin Z, Johnson LC, Weissbach H, Brot N, Lively MO, Lowther WT. Free methionine-(R)-sulfoxide reductase from Escherichia coli reveals a new GAF domain function. Proc Natl Acad Sci U S A. 2007;104(23):9597-9602.

Pemble CW IV, Johnson LC, Kridel SJ, Lowther WT. Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat. Nat Struct Mol Biol. 2007;14(8):704-709.

Kridel SJ, Lowther WT, Pemble CW IV. Fatty acid synthase inhibitors: new directions for oncology. Expert Opin Investig Drugs. 2007;16(11):1817-1829.

Jonsson TJ, Lowther WT. The peroxiredoxin repair proteins. Subcell Biochem. 2007;44():115-141.

Jonsson TJ, Johnson LC, Lowther WT. Structure of the sulfiredoxin-peroxiredoxin complex reveals basis for cysteine sulfinic acid repair [abstract]. Free Radic Biol Med. 2007;43(Suppl 1):S110.

Brot N, Collet J-F, Johnson LC, Jonsson TJ, Weissbach H, Lowther WT. The thioredoxin domain of Neisseria gonorrhoeae PilB can use electrons from DsbD to reduce downstream methionine sulfoxide reductases. J Biol Chem. 2006;281(43):32668-75.